Biofrontera (BFRI) Price & Analysis

Compare

178 Followers

BFRI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.54 - $2.22

Previous CloseN/A

Volume12.39M

Average Volume (3M)263.15K

Market Cap

$8.95M

Enterprise Value$4.41M

Total Cash (Recent Filing)$7.24M

Total Debt (Recent Filing)$5.00M

Price to Earnings (P/E)―

Beta0.16

Next Earnings

Nov 30, 2025

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding10,668,442

10 Day Avg. Volume646,935

30 Day Avg. Volume263,151

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.49

Enterprise Value/Revenue0.11

Enterprise Value/Gross Profit0.18

Enterprise Value/Ebitda-0.29

Forecast

1Y Price Target

$4.67

Price Target Upside455.95% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial PerformanceBiofrontera Inc. reported better than expected 2Q revenue and gross margins.

Product DevelopmentBiofrontera reached an important milestone by announcing preliminary results from a Phase 3 study of Ameluz that were highly statistically significant for all primary and secondary endpoints.

RestructuringThe restructuring allows Biofrontera Inc. to acquire all U.S. assets related to Ameluz and take responsibility for U.S. manufacturing, as well as regulatory, quality management, and pharmacovigilance.

Bears Say

RevenueRevenue of $8.6 million lagged the $10.6 million estimate and $10.6 million consensus.

Stock Target PriceIf the company can execute, the stock should trade closer to the comp group average of 3x 2026 revenue, or $2.75 a share, down from the previous price target of $7 a share.

Biofrontera News

Biofrontera announces last-patient-out in Phase 2b study of Ameluz topical gel

Biofrontera announced that the final patient in its Phase 2b clinical trial evaluating Ameluz for the treatment of...

13d ago

BFRI

Biofrontera Inc. appoints George Jones as chief commercial officer

Biofrontera announced the appointment of George Jones as chief commercial officer, starting August 25. In this role, Jones...

26d ago

BFRI

Biofrontera, Inc. Reports Record Sales Amid Strategic Growth

Biofrontera, Inc. (($BFRI)) has held its Q2 earnings call. Read on for the main highlights of the call....

6d ago

BFRI

Biofrontera Inc. Reports Revenue Growth Amid Strategic Restructuring

Biofrontera, Inc. ( ($BFRI) ) has released its Q2 earnings. Here is a breakdown of the information Biofrontera,...

23d ago

BFRI

Biofrontera Appoints New Chief Commercial Officer

Biofrontera ( ($BFRI) ) has issued an announcement. On August 11, 2025, Biofrontera Inc. announced the appointment of...

26d ago

BFRI

Biofrontera, Inc. (BFRI) Q2 Earnings Cheat Sheet

Biofrontera, Inc. (BFRI) is scheduled to report 2nd quarter earnings on 08/13/2025, after the market closes. Regarding Q2...

27d ago

BFRI

Biofrontera Inc. files to sell 13.6M shares of common stock for holders

17:31 EDT Biofrontera Inc. (BFRI) files to sell 13.6M shares of common stock for holders Published first on...

2M ago

BFRI

Biofrontera Finalizes Acquisition of U.S. Ameluz Rights

Biofrontera ( ($BFRI) ) just unveiled an announcement. On June 30, 2025, Biofrontera Inc. finalized an agreement with...

2M ago

BFRI

Biofrontera Restructures U.S. Rights with $11M Investment

An announcement from Biofrontera ( ($BFRI) ) is now available. On June 30, 2025, Biofrontera Inc. announced a...

2M ago

BFRI

Biofrontera Inc. price target raised to $10 from $8 at Roth Capital

Roth Capital raised the firm’s price target on Biofrontera Inc. (BFRI) to $10 from $8 and keeps a...

2M ago

BFRI

Biofrontera Inc. restructures relationship with Biofrontera AG

Biofrontera Inc. (BFRI) has acquired all U.S. Rights to Ameluz and RhodoLED from its former parent company Biofrontera...

2M ago

BFRI

Biofrontera Holds Annual Stockholders Meeting, Key Decisions Made

Biofrontera ( ($BFRI) ) just unveiled an update. On June 12, 2025, Biofrontera Inc. held its Annual Meeting...

3M ago

BFRI

Biofrontera Inc. Negotiates Cooperation Changes with Biofrontera AG

An announcement from Biofrontera ( ($BFRI) ) is now available. On June 11, 2025, Biofrontera Inc. announced that...

3M ago

BFRI

Biofrontera Inc. confirms talks on possible combination with Biofrontera AG

Biofrontera Inc. (BFRI) confirms a disclosure by the Management Board of Biofrontera AG on June 10, according to...

3M ago

BFRI

BFRI FAQ

What was Biofrontera’s price range in the past 12 months?

Biofrontera lowest stock price was $0.54 and its highest was $2.22 in the past 12 months.

What is Biofrontera’s market cap?

Biofrontera’s market cap is $8.95M.

When is Biofrontera’s upcoming earnings report date?

Biofrontera’s upcoming earnings report date is Nov 30, 2025 which is in 84 days.

How were Biofrontera’s earnings last quarter?

Biofrontera released its earnings results on Aug 13, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.15.

Is Biofrontera overvalued?

According to Wall Street analysts Biofrontera’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biofrontera pay dividends?

Biofrontera does not currently pay dividends.

What is Biofrontera’s EPS estimate?

Biofrontera’s EPS estimate is -0.42.

How many shares outstanding does Biofrontera have?

Biofrontera has 10,668,442 shares outstanding.

What happened to Biofrontera’s price movement after its last earnings report?

Biofrontera reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went up 2.105%.

Which hedge fund is a major shareholder of Biofrontera?

Currently, no hedge funds are holding shares in BFRI

Company Description

Biofrontera

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera (BFRI) Earnings & Revenues

Historic Earnings Reports

BFRI Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Biofrontera's earnings call reflects a successful first half of 2025 marked by record sales, strategic independence, and strong financial backing, despite increased net losses and legal costs. The overall sentiment is buoyed by positive operational changes and future growth prospects.View all BFRI earnings summaries

BFRI Stock 12 Month Forecast

Average Price Target

$4.67

▲(455.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.7292307692307693,2.4184615384615387,3.107692307692308,3.7969230769230773,4.486153846153846,5.175384615384616,5.8646153846153855,6.5538461538461545,7.243076923076924,7.932307692307693,8.621538461538464,9.310769230769232,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.3192307692307692,1.5984615384615384,1.8776923076923078,2.1569230769230767,2.436153846153846,2.7153846153846155,2.9946153846153845,3.273846153846154,3.5530769230769232,3.832307692307692,4.111538461538462,4.390769230769231,{"y":4.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.036923076923077,1.0338461538461539,1.0307692307692309,1.0276923076923077,1.0246153846153847,1.0215384615384615,1.0184615384615385,1.0153846153846153,1.0123076923076924,1.0092307692307692,1.0061538461538462,1.003076923076923,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.89,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >